Use of cell salvage and HBOC-201 in a pregnant Jehovah's Witness with sickle beta+thalassaemia undergoing emergency caesarean section.
Julia C FortierShiyi PangSoleil SchutteMarc Stuart ZumbergAnita RajasekharPublished in: BMJ case reports (2022)
Patients with severe anaemia who refuse or cannot safely receive red cell transfusion present challenges during pregnancy, delivery and the postpartum period. Strategies including HBOC-201 (Hemopure) and intraoperative use of cell salvage have been used in non-pregnant patients to improve oxygen carrying capacity; however, these products pose unique risks in pregnant patients, those with sickle cell disease (SCD) and those undergoing caesarean section (C-section). We describe a case of a pregnant sickle beta+thalasasaemia patient who presented at 27 weeks gestation with pre-eclampsia and severe anaemia. As a Jehovah's Witness, she declined allogenic blood transfusion. The patient successfully underwent emergent C-section with cell salvage and received HBOC-201 immediately after delivery, during the operative procedure. To our knowledge, this is the first published report documenting a Jehovah's Witness patient with SCD who successfully received cell salvage and then HBOC-201 immediately postdelivery.
Keyphrases
- single cell
- end stage renal disease
- cell therapy
- pregnant women
- newly diagnosed
- healthcare
- ejection fraction
- chronic kidney disease
- case report
- public health
- peritoneal dialysis
- preterm infants
- stem cells
- mesenchymal stem cells
- randomized controlled trial
- minimally invasive
- bone marrow
- cardiac surgery
- patient reported outcomes
- human health